Drug Search Results
More Filters [+]

JNJ-26483327

Alternative Names: jnj-26483327, jnj26483327, jnj 26483327
Latest Update: 2010-04-26
Latest Update Note: Clinical Trial Update

Product Description

JNJ-26483327, a multi-targeted reversible kinase inhibitor, is a new drug in development for treatment of cancer (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00676299)

Mechanisms of Action: TK Inhibitor

Novel Mechanism: No

Modality: N/A

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for JNJ-26483327

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Mouth Cancer|Acute Respiratory Distress Syndrome|Heart Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CR011881

P1

Completed

Mouth Cancer|Acute Respiratory Distress Syndrome|Heart Cancer

None

Recent News Events

Date

Type

Title